MARKET

MYGN

MYGN

Myriad Genetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.12
-0.08
-0.33%
Closed 17:58 11/13 EST
OPEN
24.17
PREV CLOSE
24.20
HIGH
24.66
LOW
24.03
VOLUME
686.37K
TURNOVER
--
52 WEEK HIGH
48.40
52 WEEK LOW
20.10
MARKET CAP
1.79B
P/E (TTM)
-115.0763
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MYGN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MYGN News

  • CLASS ACTION UPDATE: Brodsky & Smith, LLC Reminds Investors of Looming Deadlines to File Lead Plaintiff Motions Related to the Following Companies: MYGN, MTCH, COF
  • ACCESSWIRE.1h ago
  • Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tencent, Myriad Genetics, Overstock.com, and Waitr Holdings and Encourages Investors to Contact the Firm
  • GlobeNewswire.13h ago
  • Pawar Law Group Reminds Investors of NOV. 26 Deadline in Securities Class Action Lawsuit Against Myriad Genetics, Inc. MYGN
  • GlobeNewswire.17h ago
  • IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
  • ACCESSWIRE.18h ago

More

Industry

Medical Equipment, Supplies & Distribution
+0.36%
Healthcare Equipment & Supplies
+0.49%

Hot Stocks

Name
Price
%Change

About MYGN

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.
More

Webull offers Myriad Genetics, Inc. (MYGN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.